{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"type-1-interferonopathy","columns":[],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":[],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":[],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"not available","narrativeSourceChanges":[],"records":0,"sourceGroups":{}},"features":[],"ledeHtml":"Conditions in which increased type 1 interferon signaling leads to autoimmune and neurological disorders. These disorders are caused by variants in genes involved in nucleic acid metabolism, sensing, and the innate immune response.","mondoId":"MONDO:0700264","node":{"canonicalSlug":"type-1-interferonopathy","comparisons":[],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"definition-only","matchMethod":"same-ontology-node","name":"type 1 interferonopathy","paragraphs":["Conditions in which increased type 1 interferon signaling leads to autoimmune and neurological disorders. These disorders are caused by variants in genes involved in nucleic acid metabolism, sensing, and the innate immune response."],"scope":"exact","source":"MONDO","upstream":"https://clinicalgenome.org/affiliation/40060/, https://clinicalgenome.org/affiliation/40107/, https://clinicalgenome.org/affiliation/40123/","url":"https://monarchinitiative.org/MONDO:0700264"},"ownColumnKeys":[],"publication":"published","relationships":[{"kind":"parent","label":"autoinflammatory syndrome","mondoId":"MONDO:0019751","slug":null},{"kind":"child","label":"TREX1-related type 1 interferonopathy","mondoId":"MONDO:0700256","slug":"trex1-related-type-1-interferonopathy"},{"kind":"child","label":"RNASEH2B-related type 1 interferonopathy","mondoId":"MONDO:0700257","slug":"rnaseh2b-related-type-1-interferonopathy"},{"kind":"child","label":"RNASEH2C-related type 1 interferonopathy","mondoId":"MONDO:0700258","slug":"rnaseh2c-related-type-1-interferonopathy"},{"kind":"child","label":"RNASEH2A-related type 1 interferonopathy","mondoId":"MONDO:0700259","slug":"rnaseh2a-related-type-1-interferonopathy"},{"kind":"child","label":"SAMHD1-related type 1 interferonopathy","mondoId":"MONDO:0700260","slug":"samhd1-related-type-1-interferonopathy"},{"kind":"child","label":"ADAR-related type 1 interferonopathy","mondoId":"MONDO:0700261","slug":"adar-related-type-1-interferonopathy"},{"kind":"child","label":"IFIH1-related type 1 interferonopathy","mondoId":"MONDO:0700262","slug":"ifih1-related-type-1-interferonopathy"},{"kind":"child","label":"RNU7-1-related type 1 interferonopathy","mondoId":"MONDO:0700263","slug":"rnu7-1-related-type-1-interferonopathy"},{"kind":"child","label":"type 1 interferonopathy of childhood","mondoId":"MONDO:0957408","slug":null}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"Public source record is not available in the frozen inputs","source":"GARD","url":"https://rarediseases.info.nih.gov/diseases/21957"}],"translation":"pending"},"records":[],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0700264\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>definition-only</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>same-ontology-node</dd><dt>Upstream attribution</dt><dd>https://clinicalgenome.org/affiliation/40060/, https://clinicalgenome.org/affiliation/40107/, https://clinicalgenome.org/affiliation/40123/</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Conditions in which increased type 1 interferon signaling leads to autoimmune and neurological disorders. These disorders are caused by variants in genes involved in nucleic acid metabolism, sensing, and the innate immune response.</p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0700264\" rel=\"noreferrer\">MONDO</a></p>","key":"overview","title":"Brief description"}],"sharedSources":[],"slug":"type-1-interferonopathy","sourceDocuments":[{"name":"MONDO: type 1 interferonopathy","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0700264"}],"sourceNote":"","synonyms":[],"takeawayHtml":"","title":"type 1 interferonopathy"},"schemaVersion":1}
